To cite this paper use one of the standards below:
Spinal muscular atrophy (SMA) is a rare and incurable genetic disorder characterized by the degeneration of motor neurons caused by mutations in the SMN1 gene. These mutations lead to reduced levels of the survival motor neuron (SMN) protein and progressive muscle atrophy. The limited permeability of the blood-brain barrier (BBB) restricts drug bioavailability in the central nervous system (CNS), hindering the treatment of the disease. In this study, we aimed to develop liposomal nanosystems for the co-encapsulation of olesoxime (OLX), indoprofen (IDF), and risdiplam (RDP) for intranasal delivery as a therapeutic strategy for SMA. Drug-loaded liposomes were synthesized using the solvent injection method, exhibiting an average diameter of 93±9 nm, a polydispersity index (PDI) of 0.22±0.02 and Zeta potential (ZP) of 0±2 mV, physicochemical characteristics compatible with intranasal administration. The encapsulation efficiency was 92±19% for OLX, 32±5% for IDF and 32±4% for RDP, demonstrating the feasibility of simultaneously co-encapsulating the three drugs within the nanosystem. Atomic force microscopy (AFM) and transmission electron microscopy (TEM) analyses revealed spherical morphology and a homogeneous size distribution, with diameters below 130 nm and 100 nm, respectively. Furthermore, the drug-loaded liposomes maintained stable size, PDI, and ZP for 8 weeks and exhibited no cytotoxicity at concentrations below 109 particles/mL in cell viability assays using NSC-34 cells. Additional studies will be conducted to investigate the cellular uptake of the liposomes by NSC-34 cells, as well as their ability to synergistically modulate SMN protein expression in a disease-relevant cellular model. These findings indicate that the liposomal nanosystem represents a promising platform for the combined intranasal delivery of drugs as a therapeutic strategy for SMA.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper